What is Arzeda?
Arzeda operates at the intersection of physics-based computational protein design, machine learning, and high-throughput lab automation. The company specializes in creating and manufacturing novel proteins that serve as the building blocks for sustainable products across the food, nutrition, advanced materials, and pharmaceutical industries. By moving beyond the limitations of natural evolution, Arzeda provides Fortune 500 partners with the tools to develop healthier, more sustainable solutions, effectively bridging the gap between digital design and physical manufacturing in the bioeconomy.
How much funding has Arzeda raised?
Arzeda has raised a total of $91.7M across 6 funding rounds:
Series A
$15.2M
Debt
$350K
Debt
$599K
Series B
$33M
Other Financing Round
$38M
Private Equity
$4.5M
Series A (2017): $15.2M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2021): $599K supported by PPP
Series B (2022): $33M featuring Circulate Capital, Bioeconomy Capital, UMI, Bunge Ventures, Casdin Capital, Lewis & Clark Agrifood, OS Fund, and Conti Ventures
Other Financing Round (2024): $38M backed by Sofinnova Partners, Sucden, and Bunge Ventures
Private Equity (2025): $4.5M, investors not publicly disclosed
Key Investors in Arzeda
Circulate Capital
Circulate Capital is a leading investment management firm focused on the circular economy, partnering with global brands and institutional investors to fund sustainable initiatives that transform recycling and plastic supply chains.
Bioeconomy Capital
Bioeconomy Capital is an early-stage venture capital firm that specializes in companies that are laying the foundation for the rapidly expanding bioeconomy, focusing on biological engineering and production technologies.
Casdin Capital
Casdin Capital brings deep expertise and a long-term perspective to financing the next generation of life science innovation, with a strong focus on diagnostics and molecular information.
What's next for Arzeda?
With this latest infusion of capital, Arzeda is well-positioned to scale its proprietary protein design platform and expand its commercial footprint. The company's strategic roadmap focuses on deepening its partnerships with industrial leaders to accelerate the time-to-market for bio-based innovations. As the demand for sustainable manufacturing processes intensifies, Arzeda is poised to capitalize on its technological moat, driving further adoption of its synthetic biology solutions in high-growth markets and reinforcing its role as a critical infrastructure provider for the next generation of life science products.
See full Arzeda company page
